Cambrex to Invest 30 Million USD to Expand Manufacturing Center of Excellence at High Point, NC Facility
PR92139
EAST RUTHERFORD, N.J., Oct. 7, 2021 /PRNewswire=KYODO JBN/ --
Cambrex today announced that it is expanding its manufacturing center of
excellence in High Point, NC. The $30+ million investment is designed to meet
the continually growing demand for small molecule development and manufacturing
services.
The expansion will add new chemistry laboratories, two new clinical
manufacturing suites and include a small-scale commercial manufacturing
operation with three work centers and 2,000 Litre reactors.
This investment will provide Cambrex with the capabilities to handle the latest
R&D process research tools and techniques, increase Cambrex's equipment
offerings to support customer's speed to market goals, and provide a dedicated
facility for orphan drugs and niche therapies (annual volumes <500kg).
Alongside the new infrastructure which focuses on energy savings and
efficiency, 78 new jobs will be created in the area. New positions include
operations, scientists, quality assurance and administrative personnel.
"Cambrex's mission is to support our pharmaceutical customers in the
development and manufacturing of new therapies that improve human health," said
Thomas Loewald, Cambrex CEO. "As a result of our High Point team's commitment
to providing our customers best-in-class technical expertise, innovative
chemistry, and engineering solutions, the facility has seen rapid growth in
demand for our development and manufacturing services. We are extremely
excited about this expansion in North Carolina, which would not have been
possible without the support of the State's leadership and economic development
programs, and their focus on nurturing the region's skilled and diverse
workforce."
A performance-based grant of $200,000 from the One North Carolina Fund will
help with Cambrex's expansion. The One North Carolina Fund provides financial
assistance to local governments to help attract economic investment and to
create jobs.
About Cambrex
Cambrex is the leading small molecule company that provides drug substance,
drug product, and analytical services across the entire drug lifecycle. The
company provides customers with an end-to-end partnership for the research,
development, and manufacture of small molecule therapeutics. With over 40
years' experience and a growing team of over 2,200 experts servicing global
clients from sites in North America and Europe, Cambrex is a trusted partner in
branded and generic markets for API and dosage form development and
manufacturing.
Cambrex offers a range of specialist drug substance technologies and
capabilities, including biocatalysis, continuous flow, controlled substances,
solid state science, material characterization, and highly potent APIs. In
addition, Cambrex can support conventional dosage forms, including oral solids,
semi-solids, and liquids, and has the expertise to manufacture specialist
dosage forms such as modified-release, fixed-dose combination, pediatric,
bi-layer tablets, stick packs, topicals, controlled substances, sterile and
non-sterile ointments.
For more information, visit www.cambrex.com
Contact: Natalee Campbell
Email: press@cambrex.com
Phone: +1 919 544 8638
Logo - https://mma.prnewswire.com/media/1198585/Cambrex_Logo.jpg
Source: Cambrex
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。